The tyrosine phosphatase Shp2 (PTPN11) in cancer

Cancer and Metastasis Reviews

Volumn 27, Issue 2, 2008, Pages 179-192

  Chan, Gordon ^a   Kalaitzidis, Demetrios ^b   Neel, Benjamin G ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; Cancer; Helicobacter pylori; Juvenile myelomonocytic leukemia (JMML); Leukemia; Noonan syndrome; Protein tyrosine phosphatase (PTP); PTPN11; Shp 2; Shp2; Signal transduction

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE SHP 2;

BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; GERM LINE; HELICOBACTER PYLORI; HEMATOLOGIC MALIGNANCY; HUMAN; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEOPARD SYNDROME; LEUKEMOGENESIS; MUTATION; NEOPLASM; NONHUMAN; NOONAN SYNDROME; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LEOPARD SYNDROME; MUTATION; NEOPLASMS; NOONAN SYNDROME; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION;

EID: 43049093663     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-008-9126-y     Document Type: Review

References (137)

1. Mohi, M. G., & Neel, B. G. (2007). The role of Shp2 (PTPN11) in cancer. Current Opinion in Genetics & Development, 17(1), 23-30.
2. Neel, B. G., Gu, H., & Pao, L. (2003). The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends in Biochemical Sciences, 28(6), 284-293.
3. Pao, L. I., Badour, K., Siminovitch, K. A., & Neel, B. G. (2007). Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annual Review of Immunology, 25, 473-523.
4. Feng, G. S. (1999). Shp-2 tyrosine phosphatase: signaling one cell or many. Experimental Cell Research, 253(1), 47-54.
5. Chan, R. J., & Feng, G. S. (2007). PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood, 109(3), 862-867.
6. Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., et al. (2001). Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nature Genetics, 29(4), 465-468.
7. Tartaglia, M., & Gelb, B. D. (2005). Noonan syndrome and related disorders: Genetics and pathogenesis. Annual Review of Genomics and Human Genetics, 6, 45-68.
8. Tartaglia, M., Niemeyer, C. M., Shannon, K. M., & Loh, M. L. (2004). SHP-2 and myeloid malignancies. Current Opinion in Hematology, 11(1), 44-50.
9. Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., et al. (2003). Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics, 34(2), 148-150.
10. Loh, M. L., Vattikuti, S., Schubbert, S., Reynolds, M. G., Carlson, E., Lieuw, K. H., et al. (2004). Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood, 103(6), 2325-2331.
11. Neel, B., Gu, H., & Pao, L. (2003). SH2 domain-containing protein tyrosine phosphatases. In R. A. Bradshaw, & E. A. Dennis (Eds.) Handbook cell signaling pp. 707-730. Amsterdam: Elsevier.
12. Gelb, B. D., & Tartaglia, M. (2006). Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Human Molecular Genetics, 15(Spec No 2), R220-226.
13. Tonks, N. K., & Neel, B. G. (2001). Combinatorial control of the specificity of protein tyrosine phosphatases. Current Opinion in Cell Biology, 13(2), 182-195.
14. Van Vactor, D., O'Reilly, A. M., & Neel, B. G. (1998). Genetic analysis of protein tyrosine phosphatases. Current Opinion in Genetics & Development, 8(1), 112-126.
15. Araki, T., Nawa, H., & Neel, B. G. (2003). Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. Journal of Biological Chemistry, 278(43), 41677-41684.
16. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., & Shoelson, S. E. (1998). Crystal structure of the tyrosine phosphatase SHP-2. Cell, 92(4), 441-450.
17. Barford, D., & Neel, B. G. (1998). Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure, 6(3), 249-254.
18. O'Reilly, A. M., Pluskey, S., Shoelson, S. E., & Neel, B. G. (2000). Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Molecular and Cellular Biology, 20(1), 299-311.
19. Zhang, S. Q., Yang, W., Kontaridis, M. I., Bivona, T. G., Wen, G., Araki, T., et al. (2004). Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Molecular Cell, 13(3), 341-355.
20. Ren, Y., Meng, S., Mei, L., Zhao, Z. J., Jove, R., & Wu, J. (2004). Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. Journal of Biological Chemistry, 279(9), 8497-8505.
21. Bertotti, A., Comoglio, P. M., & Trusolino, L. (2006). Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. Journal of Cell Biology, 175(6), 993-1003.
22. Klinghoffer, R. A., & Kazlauskas, A. (1995). Identification of a putative Syp substrate, the PDGF beta receptor. Journal of Biological Chemistry, 270(38), 22208-22217.
23. Agazie, Y. M., & Hayman, M. J. (2003). Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Molecular and Cellular Biology, 23(21), 7875-7886.
24. Cleghon, V., Feldmann, P., Ghiglione, C., Copeland, T. D., Perrimon, N., Hughes, D. A., et al. (1998). Opposing actions of CSW and RasGAP modulate the strength of Torso RTK signaling in the Drosophila terminal pathway. Molecular Cell, 2(6), 719-727.
25. Hanafusa, H., Torii, S., Yasunaga, T., Matsumoto, K., & Nishida, E. (2004). Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. Journal of Biological Chemistry, 279(22), 22992-22995.
26. Jarvis, L. A., Toering, S. J., Simon, M. A., Krasnow, M. A., & Smith-Bolton, R. K. (2006). Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases. Development, 133(6), 1133-1142.
27. Zhang, S. Q., Tsiaras, W. G., Araki, T., Wen, G., Minichiello, L., Klein, R., et al. (2002). Receptor-specific regulation of phosphatidylinositol 3'′-kinase activation by the protein tyrosine phosphatase Shp2. Molecular and Cellular Biology, 22(12), 4062-4072.
28. Mattoon, D. R., Lamothe, B., Lax, I., & Schlessinger, J. (2004). The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol, 2, 24.
29. Shi, Z. Q., Lu, W., & Feng, G. S. (1998). The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases. Journal of Biological Chemistry, 273(9), 4904-4908.
30. You, M., Flick, L. M., Yu, D., & Feng, G. S. (2001). Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. Journal of Experimental Medicine, 193(1), 101-110.
31. Schoenwaelder, S. M., Petch, L. A., Williamson, D., Shen, R., Feng, G. S., & Burridge, K. (2000). The protein tyrosine phosphatase Shp-2 regulates RhoA activity. Current Biology, 10(23), 1523-1526.
32. Kontaridis, M. I., Eminaga, S., Fornaro, M., Zito, C. I., Sordella, R., Settleman, J., et al. (2004). SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Molecular and Cellular Biology, 24(12), 5340-5352.
33. Uhlen, P., Burch, P. M., Zito, C. I., Estrada, M., Ehrlich, B. E., & Bennett, A. M. (2006). Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. Proceedings of the National Academy of Sciences of the United States of America, 103(7), 2160-2165.
34. Walter, A. O., Peng, Z. Y., & Cartwright, C. A. (1999). The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism. Oncogene, 18(11), 1911-1920.
35. Yu, W. M., Hawley, T. S., Hawley, R. G., & Qu, C. K. (2003). Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene, 22(38), 5995-6004.
36. Schubbert, S., Zenker, M., Rowe, S. L., Boll, S., Klein, C., Bollag, G., et al. (2006). Germline KRAS mutations cause Noonan syndrome. Nature Genetics, 38(3), 331-336.
37. Carta, C., Pantaleoni, F., Bocchinfuso, G., Stella, L., Vasta, I., Sarkozy, A., et al. (2006). Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. American Journal of Human Genetics, 79(1), 129-135.
38. Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., et al. (2007). Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nature Genetics, 39(1), 70-74.
39. Tartaglia, M., Pennacchio, L. A., Zhao, C., Yadav, K. K., Fodale, V., Sarkozy, A., et al. (2007). Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nature Genetics, 39(1), 75-79.
40. Razzaque, M. A., Nishizawa, T., Komoike, Y., Yagi, H., Furutani, M., Amo, R., et al. (2007). Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nature Genetics, 39, 1013-1017.
41. Pandit, B., Sarkozy, A., Pennacchio, L. A., Carta, C., Oishi, K., Martinelli, S., et al. (2007). Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nature Genetics, 39, 1007-1012.
42. Tartaglia, M., Martinelli, S., Iavarone, I., Cazzaniga, G., Spinelli, M., Giarin, E., et al. (2005). Somatic PTPN11 mutations in childhood acute myeloid leukaemia. British Journal of Haematology, 129(3), 333-339.
43. Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., et al. (2004). Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Research, 64(24), 8816-8820.
44. Loh, M. L., Reynolds, M. G., Vattikuti, S., Gerbing, R. B., Alonzo, T. A., Carlson, E., et al. (2004). PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia, 18(11), 1831-1834.
45. Tartaglia, M., Martinelli, S., Cazzaniga, G., Cordeddu, V., Iavarone, I., Spinelli, M., et al. (2004). Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood, 104(2), 307-313.
46. Yamamoto, T., Isomura, M., Xu, Y., Liang, J., Yagasaki, H., Kamachi, Y., et al. (2006). PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. Leukemia Research, 30(9), 1085-1089.
47. Martinelli, S., Carta, C., Flex, E., Binni, F., Cordisco, E. L., Moretti, S., et al. (2006). Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genetics and Cytogenetics, 166(2), 124-129.
48. Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science, 314(5797), 268-274.
49. Tartaglia, M., Kalidas, K., Shaw, A., Song, X., Musat, D. L., van der Burgt, I., et al. (2002). PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. American Journal of Human Genetics, 70(6), 1555-1563.
50. Kosaki, K., Suzuki, T., Muroya, K., Hasegawa, T., Sato, S., Matsuo, N., et al. (2002). PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. Journal of Clinical Endocrinology and Metabolism, 87(8), 3529-3533.
51. Keilhack, H., David, F. S., McGregor, M., Cantley, L. C., & Neel, B. G. (2005). Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. Journal of Biological Chemistry, 280(35), 30984-30993.
52. Niihori, T., Aoki, Y., Ohashi, H., Kurosawa, K., Kondoh, T., Ishikiriyama, S., et al. (2005). Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia. Journal of Human Genetics, 50(4), 192-202.
53. Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., et al. (2006). Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. American Journal of Human Genetics, 78(2), 279-290.
54. Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., et al. (2004). Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nature Medicine, 10(8), 849-857.
55. Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. (2006). PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. Journal of Biological Chemistry, 281(10), 6785-6792.
56. Hanna, N., Montagner, A., Lee, W. H., Miteva, M., Vidal, M., Vidaud, M., et al. (2006). Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1. FEBS Letters, 580(10), 2477-2482.
57. Conti, E., Dottorini, T., Sarkozy, A., Tiller, G. E., Esposito, G., Pizzuti, A., et al. (2003). A novel PTPN11 mutation in LEOPARD syndrome. Human Mutation, 21(6), 654.
58. Brems, H., Chmara, M., Sahbatou, M., Denayer, E., Taniguchi, K., Kato, R., et al. (2007). Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nature Genetics, 39(9), 1120-1126.
59. Sarkozy, A., Conti, E., Digilio, M. C., Marino, B., Morini, E., Pacileo, G., et al. (2004). Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome. Journal of Medical Genetics, 41(5), e68.
60. Ucar, C., Calyskan, U., Martini, S., & Heinritz, W. (2006). Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive). Journal of Pediatric Hematology Oncology, 28(3), 123-125.
61. Keren, B., Hadchouel, A., Saba, S., Sznajer, Y., Bonneau, D., Leheup, B., et al. (2004). PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience. Journal of Medical Genetics, 41(11), e117.
62. Merks, J. H., Caron, H. N., & Hennekam, R. C. (2005). High incidence of malformation syndromes in a series of 1,073 children with cancer. American Journal of Medical Genetics, 134(2), 132-143.
63. Xu, R., Yu, Y., Zheng, S., Zhao, X., Dong, Q., He, Z., et al. (2005). Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood, 106(9), 3142-3149.
64. Chan, R. J., Leedy, M. B., Munugalavadla, V., Voorhorst, C. S., Li, Y., Yu, M., et al. (2005). Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood, 105(9), 3737-3742.
65. Mohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., et al. (2005). Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell, 7(2), 179-191.
66. Yu, W. M., Daino, H., Chen, J., Bunting, K. D., & Qu, C. K. (2006). Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling. Journal of Biological Chemistry, 281(9), 5426-5434.
67. Emanuel, P. D., Shannon, K. M., & Castleberry, R. P. (1996). Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Molecular Medicine Today, 2(11), 468-475.
68. Schubbert, S., Shannon, K., & Bollag, G. (2007). Hyperactive Ras in developmental disorders and cancer. Nature Reviews. Cancer, 7(4), 295-308.
69. Kratz, C. P., Niemeyer, C. M., Thomas, C., Bauhuber, S., Matejas, V., Bergstrasser, E., et al. (2007). Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. Leukemia, 21(5), 1108-1109.
70. Schubbert, S., Lieuw, K., Rowe, S. L., Lee, C. M., Li, X., Loh, M. L., et al. (2005). Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood, 106(1), 311-317.
71. Zhang, Y. Y., Vik, T. A., Ryder, J. W., Srour, E. F., Jacks, T., Shannon, K., et al. (1998). Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. Journal of Experimental Medicine, 187(11), 1893-1902.
72. Le, D. T., Kong, N., Zhu, Y., Lauchle, J. O., Aiyigari, A., Braun, B. S., et al. (2004). Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood, 103(11), 4243-4250.
73. Donovan, S., See, W., Bonifas, J., Stokoe, D., & Shannon, K. M. (2002). Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell, 2(6), 507-514.
74. Largaespada, D. A., Brannan, C. I., Jenkins, N. A., & Copeland, N. G. (1996). Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nature Genetics, 12(2), 137-143.
75. Bollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., et al. (1996). Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nature Genetics, 12(2), 144-148.
76. Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., et al. (2004). Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proceedings of the National Academy of Sciences of the United States of America, 101(2), 597-602.
77. Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., et al. (2004). Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. Journal of Clinical Investigation, 113(4), 528-538.
78. Li, S., Gillessen, S., Tomasson, M. H., Dranoff, G., Gilliland, D. G., & Van Etten, R. A. (2001). Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood, 97(5), 1442-1450.
79. Zhang, Y., Taylor, B. R., Shannon, K., & Clapp, D. W. (2001). Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. Journal of Clinical Investigation, 108(5), 709-715.
80. Chen, Y., Wen, R., Yang, S., Schuman, J., Zhang, E. E., Yi, T., et al. (2003). Identification of Shp-2 as a Stat5A phosphatase. Journal of Biological Chemistry, 278(19), 16520-16527.
81. Huang, W., Saberwal, G., Horvath, E., Zhu, C., Lindsey, S., & Eklund, E. A. (2006). Leukemia-associated, constitutively active mutants of SHP2 protein tyrosine phosphatase inhibit NF1 transcriptional activation by the interferon consensus sequence binding protein. Molecular and Cellular Biology, 26(17), 6311-6332.
82. Holtschke, T., Lohler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., et al. (1996). Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell, 87(2), 307-317.
83. Kautz, B., Kakar, R., David, E., & Eklund, E. A. (2001). SHP1 protein-tyrosine phosphatase inhibits gp91PHOX and p67PHOX expression by inhibiting interaction of PU.1, IRF1, interferon consensus sequence-binding protein, and CREB-binding protein with homologous Cis elements in the CYBB and NCF2 genes. Journal of Biological Chemistry, 276(41), 37868-37878.
84. Lindsey, S., Huang, W., Wang, H., Horvath, E., Zhu, C., & Eklund, E. A. (2007). Activation of SHP2 protein-tyrosine phosphatase increases HoxA10-induced repression of the genes encoding gp91(PHOX) and p67(PHOX). Journal of Biological Chemistry, 282(4), 2237-2249.
85. Mason, J. M., Morrison, D. J., Basson, M. A., & Licht, J. D. (2006). Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends in Cell Biology, 16(1), 45-54.
86. Basson, M. A., Akbulut, S., Watson-Johnson, J., Simon, R., Carroll, T. J., Shakya, R., et al. (2005). Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Developmental Cell, 8(2), 229-239.
87. Taketomi, T., Yoshiga, D., Taniguchi, K., Kobayashi, T., Nonami, A., Kato, R., et al. (2005). Loss of mammalian Sprouty2 leads to enteric neuronal hyperplasia and esophageal achalasia. Nature Neuroscience, 8(7), 855-857.
88. Shim, K., Minowada, G., Coling, D. E., & Martin, G. R. (2005). Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Developmental Cell, 8(4), 553-564.
89. Klein, O. D., Minowada, G., Peterkova, R., Kangas, A., Yu, B. D., Lesot, H., et al. (2006). Sprouty genes control diastema tooth development via bidirectional antagonism of epithelial-mesenchymal FGF signaling. Developmental Cell, 11(2), 181-190.
90. Taniguchi, K., Ayada, T., Ichiyama, K., Kohno, R., Yonemitsu, Y., Minami, Y., et al. (2007). Sprouty2 and Sprouty4 are essential for embryonic morphogenesis and regulation of FGF signaling. Biochemical and Biophysical Research Communications, 352(4), 896-902.
91. Wakioka, T., Sasaki, A., Kato, R., Shouda, T., Matsumoto, A., Miyoshi, K., et al. (2001). Spred is a Sprouty-related suppressor of Ras signalling. Nature, 412(6847), 647-651.
92. Kato, R., Nonami, A., Taketomi, T., Wakioka, T., Kuroiwa, A., Matsuda, Y., et al. (2003). Molecular cloning of mammalian Spred-3 which suppresses tyrosine kinase-mediated Erk activation. Biochemical and Biophysical Research Communications, 302(4), 767-772.
93. Nonami, A., Kato, R., Taniguchi, K., Yoshiga, D., Taketomi, T., Fukuyama, S., et al. (2004). Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. Journal of Biological Chemistry, 279(50), 52543-52551.
94. Taniguchi, K., Kohno, R., Ayada, T., Kato, R., Ichiyama, K., Morisada, T., et al. (2007). Spreds are essential for embryonic lymphangiogenesis by regulating vascular endothelial growth factor receptor 3 signaling. Molecular and Cellular Biology, 27(12), 4541-4550.
95. Inoue, H., Kato, R., Fukuyama, S., Nonami, A., Taniguchi, K., Matsumoto, K., et al. (2005). Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness. Journal of Experimental Medicine, 201(1), 73-82.
96. Bundschu, K., Knobeloch, K. P., Ullrich, M., Schinke, T., Amling, M., Engelhardt, C. M., et al. (2005). Gene disruption of Spred-2 causes dwarfism. Journal of Biological Chemistry, 280(31), 28572-28580.
97. Nobuhisa, I., Kato, R., Inoue, H., Takizawa, M., Okita, K., Yoshimura, A., et al. (2004). Spred-2 suppresses aorta-gonad-mesonephros hematopoiesis by inhibiting MAP kinase activation. Journal of Experimental Medicine, 199(5), 737-742.
98. Irish, J. M., Hovland, R., Krutzik, P. O., Perez, O. D., Bruserud, O., Gjertsen, B. T., et al. (2004). Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell, 118(2), 217-228.
99. Ornatsky, O., Baranov, V. I., Bandura, D. R., Tanner, S. D., & Dick, J. (2006). Multiple cellular antigen detection by ICP-MS. Journal of Immunological Methods, 308(1-2), 68-76.
100. Loh, M. L., Martinelli, S., Cordeddu, V., Reynolds, M. G., Vattikuti, S., Lee, C. M., et al. (2005). Acquired PTPN11 mutations occur rarely in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research, 29(4), 459-462.
101. Ren, R. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Reviews. Cancer, 5(3), 172-183.
102. O'Hare, T., Corbin, A. S., & Druker, B. J. (2006). Targeted CML therapy: controlling drug resistance, seeking cure. Current Opinion in Genetics & Development, 16(1), 92-99.
103. Million, R. P., & Van Etten, R. A. (2000). The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood, 96(2), 664-670.
104. Zhang, X., Subrahmanyam, R., Wong, R., Gross, A. W., & Ren, R. (2001). The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Molecular and Cellular Biology, 21(3), 840-853.
105. He, Y., Wertheim, J. A., Xu, L., Miller, J. P., Karnell, F. G., Choi, J. K., et al. (2002). The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood, 99(8), 2957-2968.
106. Sattler, M., & Griffin, J. D. (2001). Mechanisms of transformation by the BCR/ABL oncogene. International Journal of Hematology, 73(3), 278-291.
107. Sattler, M., Mohi, M. G., Pride, Y. B., Quinnan, L. R., Malouf, N. A., Podar, K., et al. (2002). Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell, 1(5), 479-492.
108. Scherr, M., Chaturvedi, A., Battmer, K., Dallmann, I., Schultheis, B., Ganser, A., et al. (2006). Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood, 107(8), 3279-3287.
109. Chen, J., Yu, W. M., Daino, H., Broxmeyer, H. E., Druker, B. J., & Qu, C. K. (2007). SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood, 109(2), 778-785.
110. Teal, H. E., Ni, S., Xu, J., Finkelstein, L. D., Cheng, A. M., Paulson, R. F., et al. (2006). GRB2-mediated recruitment of GAB2, but not GAB1, to SF-STK supports the expansion of Friend virus-infected erythroid progenitor cells. Oncogene, 25(17), 2433-2443.
111. Ischenko, I., Petrenko, O., Gu, H., & Hayman, M. J. (2003). Scaffolding protein Gab2 mediates fibroblast transformation by the SEA tyrosine kinase. Oncogene, 22(41), 6311-6318.
112. Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., et al. (2006). Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia, 20(4), 635-644.
113. Hou, H. A., Chou, W. C., Lin, L. I., Chen, C. Y., Tang, J. L., Tseng, M. H., et al. (2007). Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. Leukemia, in press. Nov 1.
114. Yamada, K., Nishida, K., Hibi, M., Hirano, T., & Matsuda, Y. (2001). Comparative FISH mapping of Gab1 and Gab2 genes in human, mouse and rat. Cytogenetics and Cell Genetics, 94(1-2), 39-42.
115. Bekri, S., Adelaide, J., Merscher, S., Grosgeorge, J., Caroli-Bosc, F., Perucca-Lostanlen, D., et al. (1997). Detailed map of a region commonly amplified at 11q13->q14 in human breast carcinoma. Cytogenetics and Cell Genetics, 79(1-2), 125-131.
116. Ormandy, C. J., Musgrove, E. A., Hui, R., Daly, R. J., & Sutherland, R. L. (2003). Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Research and Treatment, 78(3), 323-335.
117. Brummer, T., Schramek, D., Hayes, V. M., Bennett, H. L., Caldon, C. E., Musgrove, E. A., et al. (2006). Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. Journal of Biological Chemistry, 281(1), 626-637.
118. Bentires-Alj, M., Gil, S. G., Chan, R., Wang, Z. C., Wang, Y., Imanaka, N., et al. (2006). A role for the scaffolding adapter GAB2 in breast cancer. Nature Medicine, 12(1), 114-121.
119. Ke, Y., Wu, D., Princen, F., Nguyen, T., Pang, Y., Lesperance, J., et al. (2007). Role of Gab2 in mammary tumorigenesis and metastasis. Oncogene, 26(34), 4951-4960.
120. Hatakeyama, M. (2004). Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nature Reviews. Cancer, 4(9), 688-694.
121. Higashi, H., Tsutsumi, R., Muto, S., Sugiyama, T., Azuma, T., Asaka, M., et al. (2002). SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science, 295(5555), 683-686.
122. Tsutsumi, R., Higashi, H., Higuchi, M., Okada, M., & Hatakeyama, M. (2003). Attenuation of Helicobacter pylori CagA x SHP-2 signaling by interaction between CagA and C-terminal Src kinase. Journal of Biological Chemistry, 278(6), 3664-3670.
123. Higuchi, M., Tsutsumi, R., Higashi, H., & Hatakeyama, M. (2004). Conditional gene silencing utilizing the lac repressor reveals a role of SHP-2 in cagA-positive Helicobacter pylori pathogenicity. Cancer Science, 95(5), 442-447.
124. Tsutsumi, R., Takahashi, A., Azuma, T., Higashi, H., & Hatakeyama, M. (2006). Focal adhesion kinase is a substrate and downstream effector of SHP-2 complexed with Helicobacter pylori CagA. Molecular and Cellular Biology, 26(1), 261-276.
125. Manes, S., Mira, E., Gomez-Mouton, C., Zhao, Z. J., Lacalle, R. A., & Martinez, A. C. (1999). Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Molecular and Cellular Biology, 19(4), 3125-3135.
126. Vadlamudi, R. K., Adam, L., Nguyen, D., Santos, M., & Kumar, R. (2002). Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2. Journal of Cellular Physiology, 190(2), 189-199.
127. Oh, E. S., Gu, H., Saxton, T. M., Timms, J. F., Hausdorff, S., Frevert, E. U., et al. (1999). Regulation of early events in integrin signaling by protein tyrosine phosphatase SHP-2. Molecular and Cellular Biology, 19(4), 3205-3215.
128. Yu, D. H., Qu, C. K., Henegariu, O., Lu, X., & Feng, G. S. (1998). Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. Journal of Biological Chemistry, 273(33), 21125-21131.
129. Higashi, H., Nakaya, A., Tsutsumi, R., Yokoyama, K., Fujii, Y., Ishikawa, S., et al. (2004). Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation. Journal of Biological Chemistry, 279(17), 17205-17216.
130. Saadat, I., Higashi, H., Obuse, C., Umeda, M., Murata-Kamiya, N., Saito, Y., et al. (2007). Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature, 447(7142), 330-333.
131. Raabe, T., Riesgo-Escovar, J., Liu, X., Bausenwein, B. S., Deak, P., Maroy, P., et al. (1996). DOS, a novel pleckstrin homology domain-containing protein required for signal transduction between sevenless and Ras1 in Drosophila. Cell, 85(6), 911-920.
132. Chauhan, D., Hideshima, T., Pandey, P., Treon, S., Teoh, G., Raje, N., et al. (1999). RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene, 18(48), 6733-6740.
133. Agazie, Y. M., Movilla, N., Ischenko, I., & Hayman, M. J. (2003). The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene, 22(44), 6909-6918.
134. Bergsagel, P. L., & Kuehl, W. M. (2005). Molecular pathogenesis and a consequent classification of multiple myeloma. Journal of Clinical Oncology, 23(26), 6333-6338.
135. Burks, J., & Agazie, Y. M. (2006). Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3. Oncogene, 25(54), 7166-7179.
136. Voena, C., Conte, C., Ambrogio, C., Boeri Erba, E., Boccalatte, F., Mohammed, S., et al. (2007). The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Research, 67(9), 4278-4286.
137. Charest, A., Wilker, E. W., McLaughlin, M. E., Lane, K., Gowda, R., Coven, S., et al. (2006). ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Research, 66(15), 7473-7481.